Hepatocyte Growth Factors (HGFs) Market, By Product Type, By Type, By Source, By Application, By End User, By Country, and By Region – Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

REPORT HIGHLIGHT

Hepatocyte Growth Factors (HGFs) Market size was valued at US$ 71,786.23 Million in 2024, expanding at a CAGR of 5.6% from 2025 to 2032.
The hepatocyte growth factors (HGFs) market refers to the global ecosystem of products, technologies, and services used in the research, development, manufacturing, and application of hepatocyte growth factors. HGFs are a class of proteins that are essential for liver regeneration, embryonic development, tissue repair, angiogenesis, and tumor growth. They are primarily used in regenerative medicine, oncology, cell-based therapies, preclinical drug testing, and organ transplantation studies. This market includes recombinant proteins, HGF gene therapies, and hepatocyte-based cell culture products for both therapeutic and research applications.

Hepatocyte Growth Factors (HGFs) Market- Market Dynamics

Rising Incidence of Chronic Diseases to Propel Market Demand
The increasing prevalence of chronic diseases is a major driver of the Hepatocyte Growth Factors (HGF) market. Conditions like liver cirrhosis, hepatitis, cardiovascular disorders, and chronic kidney disease are on the rise worldwide as a result of aging populations, sedentary lifestyles, and poor dietary habits. HGFs play a crucial role in tissue regeneration, repair, and cell growth, making them a valuable tool in treating these conditions. The growing demand for advanced regenerative treatments and biologics is driving research on HGF, clinical trials, and product development. As chronic diseases impose a significant burden on healthcare systems, the demand for effective, targeted therapies drives market growth. In the United States, the Centers for Disease Control and Prevention (CDC) reported in 2024 that approximately 42% of adults have two or more chronic conditions, with 12% having at least five. These conditions account for about 90% of the nation's annual $4.1 trillion healthcare expenditure

Hepatocyte Growth Factors (HGFs) Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.6% over the forecast period (2025-2032)
Based on product type segmentation, HGF gene therapy is the fastest growing segment in the market
Based on Source segmentation, human-derived is the leading Source in 2025
Based on application segmentation, Oncology is the rapidly expanding segment the leading application in 2025
Based on End User segmentation, Pharmaceutical & Biotechnology Companies is the leading End User in 2025
On the basis of region, North America was the leading revenue generator in 2025
Hepatocyte Growth Factors (HGFs) Market- Segmentation Analysis:

The Global Hepatocyte Growth Factors (HGFs) Market is segmented on the basis of Product Type, Type, Source, Application, End User, and Region.
The market is divided into five categories based on product type: Recombinant Hepatocyte Growth Factors, Natural HGFs (Purified from Biological Sources), Synthetic Peptide Derivatives, HGF Gene Therapy Products, and Others. The HGF gene therapy products segment is expected to grow the fastest in the coming years, owing to their ability to provide targeted and effective treatment, particularly in regenerative medicine and oncology. Gene therapy allows for direct delivery of HGF to specific cells or tissues, which can reduce side effects and improve therapeutic efficacy. Techniques such as CRISPR-Cas9 enable precise gene modifications, resulting in more effective HGF gene therapies. The positive results of Phase III clinical trials involving HGF gene therapy are boosting investor confidence and encouraging additional research and development.
The market is divided into four categories based on Source: Human-Derived, Animal-Derived, Synthetic/Engineered Sources, and Others. The human-derived segment is expected to dominate the market in 2025, driven by its increased relevance and potential for clinical applications, particularly in regenerative medicine and the treatment of diseases such as liver damage. Human-derived HGFs are naturally produced by the body and are essential for various physiological processes, including liver regeneration, tissue repair, and cell proliferation. They have shown potential for treating liver diseases, heart failure, and neurological disorders. Human-derived HGFs are preferred for clinical trials and therapeutic use because they are biocompatible with the human body. Furthermore, advances in genetic engineering and stem cell technology have reinforced this leadership, allowing for the development of more effective and precisely targeted HGF therapies.

Hepatocyte Growth Factors (HGFs) Market- Geographical Insights

North America dominates the hepatocyte growth factor (HGF) market, with the largest share expected in 2025, owing to its advanced biotech industry and supportive regulatory environment. The increasing awareness of HGF's potential benefits, combined with an aging population and rising chronic disease prevalence, has fueled demand for HGFs. The region's robust healthcare system, strong emphasis on R&D, and presence of leading pharmaceutical and biotech companies have all aided market growth.
The Asia Pacific region is experiencing the most rapid growth, driven by rising chronic disease rates, expanded healthcare infrastructure, and increased healthcare spending. The governments of several Asian countries actively promote pharmaceutical development and research through funding, regulatory streamlining, and incentives for clinical trials. Clinical trials in this region are typically less expensive than those in Western countries, attracting international pharmaceutical companies. The region's large population base provides easy access to numerous potential clinical trial participants.

Hepatocyte Growth Factors (HGFs) Market- Competitive Landscape:

The competitive landscape of the hepatocyte growth factor market is characterized by the presence of several key players involved in the research, development, and commercialization of HGF products. These companies strive for a competitive advantage through innovation, strategic partnerships, and expansion into emerging markets. The market is characterized by a mix of established pharmaceutical firms, biotechnology companies, and research institutions, all of which contribute to the advancement of HGF applications across a variety of therapeutic areas. The market's dynamic nature encourages ongoing research and development to improve product efficacy, safety, and market reach. Amgen Inc., Genentech Inc., and Eli Lilly and Company are among the leading players in the hepatocyte growth factor market.

Recent Developments:

In May 2023, AnGes submitted a marketing application to the Ministry of Health, Labour, and Welfare for its gene therapy product, Collategene, which is intended to treat leg ulcers caused by chronic arterial occlusion. Following conditional approval in March 2019, this new application now seeks full approval based on the evaluation results. If approved, Collategene will be the first product to have its conditions removed since Japan implemented the regenerative medicine approval system.
In July 2023: Lonza had an agreement with ABL Bio, a pioneering Korean biologics company with a focus on bispecific antibodies for immuno-oncology and neurodegenerative diseases. The collaboration agreement between Lonza and ABL Bio supports the development and manufacturing of ABL Bio’s new bispecific antibody product.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HEPATOCYTE GROWTH FACTORS (HGFS) MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Thermo Fisher Scientific
YooYoung Pharmaceutical Co., Ltd.
F-star Therapeutics Inc.
Creative BioMart
ACROBiosystems
Kringle Pharma
Lonza Group
Galaxy Bio Tech
Merck KGaA (MilliporeSigma)
F. Hoffmann-La Roche Ltd
Galaxy Bio Tech
Sino Biological Inc.
Cell Signaling Technology
R&D Systems (Bio-Techne)
Origene Technologies
Takara Bio Inc.
GenScript Biotech Corporation
Miltenyi Biotec
BioVision Inc.
Creative Biolabs
Eli Lilly and Company (for gene therapy pipelines involving HGF)
Others

GLOBAL HEPATOCYTE GROWTH FACTORS (HGFS) MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

Recombinant Hepatocyte Growth Factors
HGF Gene Therapy Products
Synthetic Peptide Derivatives
Natural HGFs (Purified from Biological Sources)
Others
Fusion Proteins
Hybrid Growth Factors

GLOBAL HEPATOCYTE GROWTH FACTORS (HGFS) MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

Preclinical
Phase III (Ongoing)
Phase II (Approved)
Phase II (Ongoing)
Phase I

GLOBAL HEPATOCYTE GROWTH FACTORS (HGFS) MARKET, BY SOURCE- MARKET ANALYSIS, 2019 - 2032

Human-Derived
Synthetic/Engineered Sources
Animal-Derived
Others
Chimeric or Hybrid Constructs

GLOBAL HEPATOCYTE GROWTH FACTORS (HGFS) MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

Regenerative Medicine
Liver Regeneration
Kidney Repair
Wound Healing
Cell Therapy & Stem Cell Research
Toxicology and Preclinical Drug Testing
Organ Transplantation Support
Others
Neurodegenerative Diseases
Pulmonary Fibrosis
Oncology
Cancer Stem Cell Research
Tumor Metastasis Studies

GLOBAL HEPATOCYTE GROWTH FACTORS (HGFS) MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Pharmaceutical & Biotechnology Companies
CROs (Contract Research Organizations
Academic & Research Institutes
Hospitals & Transplant Centers
Others
Diagnostic Labs
Private Stem Cell Banks

GLOBAL HEPATOCYTE GROWTH FACTORS (HGFS) MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA Show more